Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • FROM THE ANALYST'S COUCH

Developing blockbuster drugs: both nature and nurture

  1. Lotte Berghauser Pont

    1. McKinsey & Co., Amsterdam, Netherlands.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  2. Jiri Keirsse

    1. McKinsey & Co., Brussels, Belgium.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  3. Rachel Moss

    1. McKinsey & Co., London, UK.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  4. Pawel Poda

    1. McKinsey & Co., Poznan, Poland.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  5. Lucas Robke

    1. McKinsey & Co., Dusseldorf, Germany.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  6. Stephan Wurzer

    1. McKinsey & Co., Munich, Germany.

    View author publications

    You can also search for this author in PubMed  Google Scholar

Bringing blockbuster drugs that address significant medical needs to market is still considered the hallmark of productive, innovative R&D. In 2018, 56% of all prescription drug sales of the top 20 pharmaceutical companies came from blockbusters, based on data from Evaluate Pharma (see Related links). This trend is set to continue, with forecasts that ~10% of total drug sales in 2024 will be from the top 10 ‘mega blockbusters’, which have peak-year sales greater than US$5 billion.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

Nature Reviews Drug Discovery 20, 421-422 (2021)

doi: https://doi.org/10.1038/d41573-020-00061-9

Supplementary Information

  1. Supplementary information

Competing Interests

All authors of this article are employees of McKinsey & Company, a management consultancy firm that works with the world’s leading biopharmaceutical companies on innovation topics. The analysis in this study was funded by McKinsey's Pharmaceuticals and Medical Products practice and undertaken independently of any other organizations.

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links